Literature DB >> 24984936

Potential C-terminal-domain inhibitors of heat shock protein 90 derived from a C-terminal peptide helix.

Jason Gavenonis1, Nicholas E Jonas1, Joshua A Kritzer2.   

Abstract

Hsp90 is a molecular chaperone implicated in many diseases including cancer and neurodegenerative disease. Most inhibitors target the ATPase site in Hsp90's N-terminal domain, with relatively few inhibitors of other domains reported to date. Here, we show that peptides derived from a short helix at the C-terminus of Hsp90 show micromolar activity as Hsp90 inhibitors in vitro. These inhibitors do not block the N-terminal domain's ATP-binding site, and thus are likely to bind at the C-terminal domain. Substitutions and helix stapling were applied to demonstrate structure-activity relationships and improve activity. These helical peptides will help guide the design of a new class of inhibitors of Hsp90's C-terminal domain.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Hsp90; Molecular chaperones; Peptides; Protein–protein interactions; Stapled helices

Mesh:

Substances:

Year:  2014        PMID: 24984936      PMCID: PMC4847944          DOI: 10.1016/j.bmc.2014.06.006

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  32 in total

1.  FTSite: high accuracy detection of ligand binding sites on unbound protein structures.

Authors:  Chi-Ho Ngan; David R Hall; Brandon Zerbe; Laurie E Grove; Dima Kozakov; Sandor Vajda
Journal:  Bioinformatics       Date:  2011-11-22       Impact factor: 6.937

2.  High-throughput assay for the identification of Hsp90 inhibitors based on Hsp90-dependent refolding of firefly luciferase.

Authors:  Lakshmi Galam; M Kyle Hadden; Zeqiang Ma; Qi-Zhuang Ye; Bo-Geon Yun; Brian S J Blagg; Robert L Matts
Journal:  Bioorg Med Chem       Date:  2007-01-04       Impact factor: 3.641

3.  Chaperone gp96-independent inhibition of endotoxin response by chaperone-based peptide inhibitors.

Authors:  Shuang Wu; Krystal Dole; Feng Hong; Abu Shadat M Noman; Jennifer Issacs; Bei Liu; Zihai Li
Journal:  J Biol Chem       Date:  2012-04-24       Impact factor: 5.157

4.  Heat shock protein 90: inhibitors in clinical trials.

Authors:  Marco A Biamonte; Ryan Van de Water; Joseph W Arndt; Robert H Scannevin; Daniel Perret; Wen-Cherng Lee
Journal:  J Med Chem       Date:  2010-01-14       Impact factor: 7.446

5.  Cytotoxic activity to acute myeloid leukemia cells by Antp-TPR hybrid peptide targeting Hsp90.

Authors:  Tomohisa Horibe; Megumi Kawamoto; Masayuki Kohno; Koji Kawakami
Journal:  J Biosci Bioeng       Date:  2012-03-17       Impact factor: 2.894

6.  A novel cell line, MDA-kb2, that stably expresses an androgen- and glucocorticoid-responsive reporter for the detection of hormone receptor agonists and antagonists.

Authors:  Vickie S Wilson; Kathy Bobseine; Christy R Lambright; L E Gray
Journal:  Toxicol Sci       Date:  2002-03       Impact factor: 4.849

7.  Rational design of shepherdin, a novel anticancer agent.

Authors:  Janet Plescia; Whitney Salz; Fang Xia; Marzia Pennati; Nadia Zaffaroni; Maria Grazia Daidone; Massimiliano Meli; Takehiko Dohi; Paola Fortugno; Yulia Nefedova; Dmitry I Gabrilovich; Giorgio Colombo; Dario C Altieri
Journal:  Cancer Cell       Date:  2005-05       Impact factor: 31.743

8.  Stepwise assembly of a glucocorticoid receptor.hsp90 heterocomplex resolves two sequential ATP-dependent events involving first hsp70 and then hsp90 in opening of the steroid binding pocket.

Authors:  Y Morishima; P J Murphy; D P Li; E R Sanchez; W B Pratt
Journal:  J Biol Chem       Date:  2000-06-16       Impact factor: 5.157

9.  The hexameric structures of human heat shock protein 90.

Authors:  Cheng-Chung Lee; Ta-Wei Lin; Tzu-Ping Ko; Andrew H-J Wang
Journal:  PLoS One       Date:  2011-05-25       Impact factor: 3.240

10.  Development and characterization of a novel C-terminal inhibitor of Hsp90 in androgen dependent and independent prostate cancer cells.

Authors:  Jeffery D Eskew; Takrima Sadikot; Pedro Morales; Alicia Duren; Irene Dunwiddie; Megan Swink; Xiaoying Zhang; Stacey Hembruff; Alison Donnelly; Roger A Rajewski; Brian S J Blagg; Jacob R Manjarrez; Robert L Matts; Jeffrey M Holzbeierlein; George A Vielhauer
Journal:  BMC Cancer       Date:  2011-10-31       Impact factor: 4.430

View more
  4 in total

1.  Synthesis and Biological Evaluation of Novobiocin Core Analogues as Hsp90 Inhibitors.

Authors:  Katherine M Byrd; Chitra Subramanian; Jacqueline Sanchez; Hashim F Motiwala; Weiya Liu; Mark S Cohen; Jeffrey Holzbeierlein; Brian S J Blagg
Journal:  Chemistry       Date:  2016-04-01       Impact factor: 5.236

2.  Synthesis and Biological Evaluation of Stilbene Analogues as Hsp90 C-Terminal Inhibitors.

Authors:  Katherine M Byrd; Caitlin N Kent; Brian S J Blagg
Journal:  ChemMedChem       Date:  2017-11-30       Impact factor: 3.466

Review 3.  Targeting Hsp90 in urothelial carcinoma.

Authors:  Mahmoud Chehab; Tiffany Caza; Kamil Skotnicki; Steve Landas; Gennady Bratslavsky; Mehdi Mollapour; Dimitra Bourboulia
Journal:  Oncotarget       Date:  2015-04-20

4.  Diversity-Oriented Stapling Yields Intrinsically Cell-Penetrant Inducers of Autophagy.

Authors:  Leila Peraro; Zhongju Zou; Kamlesh M Makwana; Ashleigh E Cummings; Haydn L Ball; Hongtao Yu; Yu-Shan Lin; Beth Levine; Joshua A Kritzer
Journal:  J Am Chem Soc       Date:  2017-05-09       Impact factor: 15.419

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.